HAYA Therapeutics

📣 Are you attending the J.P. Morgan Week 2025? Don’t miss this opportunity to connect with HAYA Therapeutics team: - Samir Ounzain, CEO & Co-founder - Daniel Blessing, CTO & Co-founder - Eric Adam, COO - Jordan Shin, CMO - Mihaela Roberts, Senior VP Finance 2024 was a transformational year for HAYA Therapeutics marked by the multi-year collaboration with Eli Lilly and Company in the identification of novel regulatory genome targets for obesity and associated metabolic diseases. We want to continue to fulfill our mission of driving innovation and bringing disease-modifying medicines to patients by leveraging HAYA’s cell-state reprogramming platform in other disease areas, at scale & speed! 🧬 We’re actively seeking strategic investors and collaborators to join us on this exciting journey. 🚀 Let’s connect and discuss how we can collaborate!🤝 #JPM2025 #Innovation #Collaboration #HAYATherapeutics #HAYA #RegulatoryGenome #ReprogrammingCells #HAYAPlatform #LncRNA

The momentum behind nucleic-acid-based therapeutics continues to grow, showcasing their potential to tackle diseases far beyond rare indications. This feature highlights recent groundbreaking deals, including HAYA Therapeutics' partnership with Eli Lilly, valued at up to $1 billion. At HAYA, we are leveraging our RNA-guided regulatory genome discovery platform to identify novel targets for obesity and related metabolic diseases, driving innovation in precision medicine. These advances emphasize the critical role of lncRNAs in addressing some of the most significant unmet medical needs. Read the full article here: https://lnkd.in/eU6BPxmz #lncRNA #PrecisionMedicine #Innovation #Biotech #NucleicAcidTherapeutics #Obesity

🚀 We’re beyond excited to share that HAYA Therapeutics has been recognized by the Swiss Innovation Agency- Innosuisse as one of their Success Stories! 🌟 Innosuisse plays a pivotal role in the Swiss start-up ecosystem, and has provided HAYA with valuable support over the years, from training to funding. It all started in 2017 with the Innosuisse Business Concept training class, where our ideas started to flourish. The subsequent Innosuisse Start-up Coaching program proved a game-changer for our co-founders, Samir Ounzain and Daniel Blessing, enabling them to turn groundbreaking science into a pioneering company developing medicines with the potential to turn diseased cells into healthy ones. 🧬 A massive shoutout to our coach, Marco Rüedi, the “Startup-Doc” for his “eyeopeners”, support and advise during this journey. And lastly a Big Thank You to our incredible team! 🙌 Want to know what makes HAYA a success story? ➡️ Don’t miss the video and article here: https://lnkd.in/eXbehs2c & https://lnkd.in/djAJ-Rx9 Let’s connect and stay tuned for more exciting news! 👉 Join the conversation, share your thoughts, and let us inspire the next wave of innovators! #SuccessStories #StartupJourney #Innosuisse #Innovation #HAYA #RegulatoryGenome #HAYATherapeutics

🚀 Pioneering a transformative breakthrough in disease treatment, HAYA Therapeutics aims to reshape patient care by harnessing the potential of Dark Genome-derived RNAs to reprogram diseased cells back to a healthy state. 🧬 With its groundbreaking approach, the company has captured the attention of pharmaceutical giant Eli Lilly and Company. 🌟💊 Riding this wave of momentum, HAYA Therapeutics is poised to elevate its cutting-edge technology onto the global stage, revolutionising the treatment of rare, common and chronic diseases. Read more: https://lnkd.in/djAJ-Rx9 With: Samir Ounzain and Daniel Blessing, PhD

🎂 In case you haven't heard the news, Biopôle marked its 20-year anniversary last week. To celebrate we're sharing a series of videos that honour our life sciences ecosystem and how far it's come in the past two decades. 💬 As Daniel Blessing, Co-Founder and CTO of HAYA Therapeutics, explains in today's film: 'In the life sciences space, Biopôle has emerged as a centre of excellence and a place for innovation in Western Switzerland. It has achieved this critical mass and we see that it attracts a lot of interest – a lot of companies are moving here.' 🙏 Thanks to Daniel and to Saad Harti, Founder and CEO of Legacy Healthcare , and Amélie Béduer, Co-Founder and CEO of Volumina Medical for their contributions to today's video.

🚀 We're Hiring! Are you looking for joining a forward-thinking organization where your expertise and skills can make a difference in fostering innovation and bring to life breakthrough disease-modifying therapeutics? 🧬 Check Our Open Position Scientist in Obesity - San Diego, CA 🇺🇲 ➡️ Apply TODAY: https://shorturl.at/Q9oLd Please, share this post with your network or tag anyone you think would be a great addition to our team! 🤝 #Hiring #JoinHAYATeam g#CareerOpportunities #NowHiring #BiotechJobs

Provocative data recently appeared in JACC Journals from Hammersley et al., which finds that myocardial fibrosis is a better predictor of outcomes in cardiomyopathy than stratification by LVEF. If we can reduce fibrosis in cardiomyopathy, will better outcomes follow? #HAYAtherapeutics is developing an Antisense Oligo (#ASO) to target activated cardiac myofibroblasts which cause myocardial fibrosis. Our goal is to change the cell state and modify the disease. https://lnkd.in/e7vwxb4X

Fibroblast phenotypic switching is increasingly recognized as a key process in cardiac fibrosis and heart failure. This article by Thomas Thum and colleagues underscores the potential of targeting the reversible transition between quiescent fibroblasts and activated myofibroblasts to mitigate fibrosis and enhance cardiac function. At HAYA Therapeutics, our lead program, HTX-001, targets WISPER, a cardiac-specific lncRNA, to reprogram activated myofibroblasts, reduce collagen deposition, and address fibrosis at its core. These insights further validate the therapeutic promise of this approach in tackling the fundamental drivers of heart failure. https://lnkd.in/eHQdkEBr

🚀 We're Hiring! Join our growing team and help us to bring to life breakthrough disease-modifying therapeutics targeting the regulatory genome with the potential for greater efficacy, safety, and accessibility than existing treatments. 🧬 New Open Position Scientist in RNA Biology, Obesity and Metabolic Diseases - San Diego, CA 🇺🇲 ➡️ Apply TODAY: https://lnkd.in/dRAHX28b Please, share this post with your network or tag anyone you think would be a great addition to our team. Discover all open positions at: https://lnkd.in/eF-T7B2c #Hiring #JoinHAYATeam #CareerOpportunities #NowHiring #BiotechJobs #HAYATherapeutics

 🎙️Another Podcast, Another Insight! 🎙️   Following the engaging conversation on The Bio Report, Samir Ounzain, HAYA's CEO & Co-founder,  shared more insights at Swisspreneur podcast in conversation with Silvan Krähenbühl. 🚀 In this latest episode Samir dives into: -       His scientific background, career path from academia to the entrepreneurial world and the foundation of HAYA Therapeutics; -       The importance of a strong team and company culture; -       The future ahead of HAYA;   👉 Whether you’re/ want to become a startup founder, a biotech or science enthusiast, this episode is a must-listen! Samir even replied to the rapid fire question — “build a pharma company yourself or getting acquired by a large pharma company one day?” Curious? 🎧 Listen to learn more: https://lnkd.in/eTZYA5Y4 A big thank you to the Swisspreneur team for this opportunity!   #Swisspreneur #Podcast #Innovation #StartupJourney #Entrepreneurship #CEOInsights #HAYA